⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25039154 | 0.76 | — | — | |
| SCHEMBL19204372 | 0.74 | — | — | |
| SCHEMBL18687188 | 0.73 | ALDH1A1 (0.37) | — | |
| SCHEMBL21504757 | 0.71 | — | — | |
| SCHEMBL19370585 | 0.69 | — | — | |
| SCHEMBL18574529 | 0.69 | — | — | |
| SCHEMBL14613814 | 0.69 | — | — | |
| SCHEMBL19069960 | 0.69 | — | — | |
| SCHEMBL24109100 | 0.69 | — | — | |
| SCHEMBL13113694 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10336773-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180118705-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9688692-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |